Published in final edited form as:

Life Sci. 2014 September 15; 113(1-2): 45–54. doi:10.1016/j.lfs.2014.07.031.

Genome-wide analysis of DNA methylation in UVB- and DMBA/TPA-induced mouse skin cancer models

Anne Yuqing Yang^{a,b,c,1}, Jong Hun Lee^{a,b,1}, Limin Shu^{a,b}, Chengyue Zhang^{a,b,c}, Zheng-Yuan Su^{a,b}, Yaoping Lu^{a,d}, Mou-Tuan Huang^{a,d}, Christina Ramirez^{b,d}, Douglas Pung^b, Ying Huang^{a,b,c}, Michael Verzi^f, Ronald P Hart^g, and Ah-Ng Tony Kong^{a,b,d,*}

^aCenter for Cancer Prevention Research, Ernest Mario School of Pharmacy, Piscataway, NJ 08854, USA

^bDepartment of Pharmaceutics, Ernest Mario School of Pharmacy, Piscataway, NJ 08854, USA

^cGraduate Program in Pharmaceutical Sciences, Ernest Mario School of Pharmacy, Piscataway, NJ 08854, USA

^dSusan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Piscataway, NJ 08854, USA

^eGraduate Program in Cellular and Molecular Pharmacology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA

^fDepartment of Genetics, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA

^gDepartment of Cell Biology and Neuroscience, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA

Abstract

Aims—Ultraviolet irradiation and carcinogens have been reported to induce epigenetic alterations, which potentially contribute to the development of skin cancer. We aimed to study the genome-wide DNA methylation profiles of skin cancers induced by ultraviolet B (UVB) irradiation and 7,12-dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoylphorbol-1,3-acetate (TPA).

Main methods—Methylated DNA immunoprecipitation (MeDIP) followed by next-generation sequencing was utilized to ascertain the DNA methylation profiles in the following common mouse skin cancer models: SKH-1 mice treated with UVB irradiation and CD-1 mice treated with DMBA/TPA. Ingenuity® pathway analysis (IPA) software was utilized to analyze the data and to identify gene interactions among the different pathways.

*Correspondence should be addressed to: Professor Ah-Ng Tony Kong, Rutgers, The State University of New Jersey, Ernest Mario School of Pharmacy, Room 228, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA, kongt@pharmacy.rutgers.edu, Phone: 848-445-6369/8, Fax: 732-445-3134.

¹These authors contributed equally to this work.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Key findings—6,003 genes in the UVB group and 5,424 genes in the DMBA/TPA group exhibited a greater than 2-fold change in CpG methylation as mapped by the IPA software. The top canonical pathways identified by IPA after the two treatments were ranked were pathways related to cancer development, cAMP-mediated signaling, G protein-coupled receptor signaling and PTEN signaling associated with UVB treatment, whereas protein kinase A signaling and xenobiotic metabolism signaling were associated with DMBA/TPA treatment. In addition, the mapped IL-6-related inflammatory pathways displayed alterations in the methylation profiles of inflammation-related genes linked to UVB treatment.

Significance—Genes with altered methylation were ranked in the UVB and DMBA/TPA models, and the molecular interaction networks of those genes were identified by the IPA software. The genome-wide DNA methylation profiles of skin cancers induced by UV irradiation or by DMBA/TPA will be useful for future studies on epigenetic gene regulation in skin carcinogenesis.

Keywords

DNA methylation; epigenetics; MeDIP-Seq; UVB; DMBA/TPA

Introduction

Accumulating evidence suggests that epigenetic DNA alterations play a crucial role in cancer initiation and development. Specifically, aberrant DNA methylation at the 5'-position of cytosine in CG dinucleotides in the cancer genome is postulated to be the most relevant epigenetic change in cancer [1]. DNA methylation affects gene expression and therefore regulates a wide range of biological processes, including proliferation, cell death, mutation and cancer initiation/promotion/progression [2, 3]. Both global hypomethylation and regional hypermethylation are characteristics of tumorigenesis [4, 5]. DNA hypermethylation at promoter regions is a predominant epigenetic mechanism for reducing the expression of tumor suppressor genes. Epigenetic silencing of tumor suppressor genes has been reported in mouse models of malignant tumors [6, 7]. Thus, the present study aimed to profile the global DNA methylation changes that occur during carcinogenesis. To address this aim, we conducted global profiling of DNA methylation changes in two representative skin carcinogenesis models, ultraviolet B (UVB)-exposed SKH-1 hairless mice and DMBA/TPA-induced carcinogenesis in CD-1 mice.

Ultraviolet irradiation has been reported to induce epigenetic alterations, which may contribute to the development of skin cancer [8]. However, the precise mechanism by which UV irradiation is related to melanomagenesis remains unclear. In addition, a method for screening epigenetically modified genes in melanoma patients needs to be established [9, 10]. Mutations in oncogenes and tumor suppressor genes have been reported in melanoma. However, most of these mutations are not present in non-melanoma skin cancer [11], suggesting a specific role for UV irradiation in melanomagenesis. In skin tumors, UV irradiation has been reported to induce epigenetic modifications and may contribute to the development of skin cancer. Epigenetic changes, such as DNA methylation and histone modification, may play a crucial role in the initiation and development of certain types of

cancer [12]. Epigenetic alterations generally represent the interface between the environment and the genome [13].

The multistage skin carcinogenesis model is established by applying a sub-threshold dose of the carcinogen DMBA followed by repetitive treatments with the tumor promoter TPA. With three well-defined stages—initiation, promotion, and progression—this model is similar to natural human tumor development. This model has been widely used to investigate the anti-tumor efficacy of chemicals and the molecular events that occur during each stage of tumor development. Several genetic alterations identified in human skin cancer patients have also been described in the mouse multistage skin carcinogenesis model, such as changes in cyclin D1 [14], TP53 [15], CDKN21 [16] and PTEN [17]. The underlying similarity in the biology of cancer between mice and humans implies that genes related to mouse tumor development may also be relevant to human tumor development.

In the present study, we used methylated DNA immunoprecipitation (MeDIP) coupled with next-generation sequencing to profile the whole genome DNA methylation patterns from the UVB and DMBA/TPA models. The MeDIP-Seq results were evaluated by Ingenuity® Pathway Analysis (IPA) to investigate genetic crosstalk and signal/function overlap. The present study included an initial assessment of genes with a modified methylation profile and the identification of interacting molecular networks in skin carcinogenesis models.

Materials and methods

Chemicals and antibodies

The chemicals used in the current study were as follows: 7,12-dimethylbenz(a)anthracene (DMBA; Sigma-Aldrich, MO, USA) and 12-O-tetradecanoylphorbol-1,3-acetate (TPA; Alexis Co., CA, USA). The 5-methylcytidine monoclonal antibody was purchased from Eurogentec., Belgium.

Mice and skin cancer induction

Two representative skin carcinogenesis models were utilized in the present study. SKH-1 hairless female mice, 7-8 weeks old, were treated with UVB (30 mJ/cm²) twice a week for 36 weeks. The UV lamps (FS72T12-UVB-HO; National Biological, Twinsburg, OH) emitted UVB (280-320 nm; 70-80% of the total energy) and ultraviolet A (320-375 nm; 20-75% of the total energy). The dose of UVB was quantified using a UVB Spectra 305 dosimeter (The Daavlin Company, Bryan, OH). The radiation was further calibrated using a research radiometer/photometer (model IL-1700; International Light Inc., Newburyport, MA). The mice were assessed twice weekly for the appearance of papillomas and carcinomas. Skin papilloma and carcinoma samples were collected, frozen in liquid nitrogen and stored at -80 °C. The epidermises of age-matched untreated mice were isolated from fresh skin as a control group.

Six-week-old female CD-1 mice were used for the DMBA/TPA-induced multistage carcinogenesis model. One day before treatment, the backs of the mice were shaved. For tumor initiation, 200 nmol DMBA in 200 µL of acetone was injected into the back skin of

the mice. Three days after DMBA treatment, 5 nmol TPA in 200 μ L of acetone was applied three times a week for 11 weeks to induce tumor promotion and progression.

Global analysis of methylated DNA

Genomic DNA (gDNA) was extracted from UV irradiation-induced tumor samples from 3 female mice and from non-irradiated epidermis samples from 3 female age-matched SKH-1 mice; from female CD-1 mice in the DMBA/TPA-induced carcinogenesis model for the MeDIP-Seq assay. gDNA was extracted using a DNeasy Kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. The gDNA was electrophoresed on an agarose gel, and the OD ratios were determined to confirm the purity and concentration of the gDNA prior to fragmentation by Covaris (Covaris, Inc., Woburn, MA USA). Fragmented gDNA was evaluated for size distribution and concentration using an Agilent Bioanalyzer 2100 and a NanoDrop spectrophotometer.

MeDIP-Seq

MeDIP was performed to analyze genome-wide methylation. MeDIP was performed using a MagMeDIP Kit from Diagenode according to the manufacturer's instructions. Methylated DNA was recovered by immunoprecipitation with antibodies specific to methylated cytosine used to separate methylated DNA fragments from unmethylated fragments, and Illumina libraries were created from the captured gDNA using NEBNext reagents (catalog# E6040; New England Biolabs, Ipswich, MA, USA). Enriched libraries were evaluated for size distribution and concentration using an Agilent Bioanalyzer 2100. The samples were then sequenced on an Illumina HiSeq2000 machine, which generated paired-end reads of 90 or 100 nucleotides (nt). The results were analyzed for data quality and exome coverage using the platform provided by DNAnexus (DNAnexus, Inc., Mountain View, CA, USA). Samples were sent to Otogenetics Corporation (Norcross, GA) for Illumina sequencing and alignment with the genome. The resulting BAM files were downloaded for analysis.

MeDIP alignments were compared with control samples using Cuffdiff 2.0.2 with no length correction [18]. Briefly, a list of overlapping regions of sequence alignment common to both the immunoprecipitated and the control samples was created and used to judge the quantitative enrichment in MeDIP samples over control samples using Cuffdiff; statistically significant peaks at 5% FDR and a minimum 4-fold difference using the Cumberbund package in R were selected [18]. Peaks were matched with adjacent annotated genes using ChIPpeakAnno [19].

Functional and pathway analysis by Ingenuity Pathway Analysis (IPA)

We analyzed lists of genes with significant fold changes (based on the *P* values; UV-induced tumor vs. control and DMBA/TPA treatment vs. control) in the methylation pattern (increases and decreases) ascertained in the MeDIP-Seq experiment using Ingenuity® Pathways Analysis 4.0 (IPA 4.0, Ingenuity Systems, www.ingenuity.com). IPA utilized gene symbols that were identified as neighboring enriched methylation peaks by ChIPpeakAnno used for all of the analyses. IPA mapped 6,003 genes in the UVB group and 5,424 genes in the DMBA/TPA group with a 2-fold change compared with the control correspondingly. Based on these fold change data, IPA identified biological functions and canonical pathways

related to UVB-induced cancer. The list of genes within canonical pathways was ranked using the ratio of the number of genes mapped to each pathway to the total number of genes in the corresponding pathway, which is presented as observations/total in Table 3.

Results

MeDIP-Seq results

Skin samples were collected from the UVB- and DMBA/TPA-induced mouse skin cancer models, and gDNA was isolated from each sample. A whole-genome DNA methylation analysis was performed on the DNA samples using the described MeDIP-Seq method. The results were analyzed in a paired manner comparing the tumor to the normal skin tissue samples for each model.

In the UVB group, 6,003 genes were identified in the two samples with a 2-fold change in methylation and an increase or decrease in gene expression. Compared with the control, 4,140 genes exhibited increased methylation, and methylation was decreased in 1,863 genes (Figure 1). However, in the DMBA/TPA treatment group, 5,424 genes were identified with a 2-fold change in peak reads between the tumor and the normal skin samples. Among these 5,424 genes, the methylation pattern was up-regulated in 3,781 genes and down-regulated in 1,643 genes. To prioritize those changes, we ranked the top 50 up-regulated (+, Table 1) and down-regulated (–, Table 2) genes based on the $\log_2$ fold change from highest to lowest, all with *P* values less than 0.05.

Pathway analysis by IPA

To ascertain the significance of the methylation changes, 6,003 genes in the UVB group and 5,424 genes in the DMBA/TPA group with a greater than 2-fold change in methylation were analyzed using the Ingenuity® Pathway Analysis (IPA) software package. The top 5 canonical signaling pathways were categorized (Table 3) based on the ratio of the number of input genes to the total number of genes in the corresponding pathway in the Ingenuity® Pathway Analysis software. Fisher's exact test was used to calculate *P* values to determine the significance of the associations of the input genes with the canonical pathways.

IPA identified more than 50 signaling pathways containing genes with significantly up-regulated and down-regulated methylation. The interleukin-6 (IL-6)-related signaling pathway was mapped by IPA to the UVB group (Figure 2); the methylation profile is presented in red (up-regulation) and green (down-regulation). Figure 2B lists the genes involved in the IL-6 signaling pathway that exhibited altered methylation (14 up-regulated and 30 down-regulated) as mapped by IPA. It has been reported that IL-6 protein expression is induced by UV irradiation [20]. Correspondingly, the MeDIP-Seq data revealed that IL-6 up-regulated methylation by 3.252-fold ($\log_2$). Based on the IPA functional pathways, skin cancer belongs to the category of mechanism of cancer. The top 5 genes related to skin cancer based on IPA are ranked by fold change in Table 4. This list includes genes with increased methylation and genes with decreased methylation that are related to skin cancer pathways by IPA.

Discussion

It was previously reported that hypermethylation of CpG islands in tumor suppressor genes occurs in human squamous cell carcinoma cell lines and in primary skin tumor tissues. Similar changes in DNA methylation patterns were observed in the multistage mouse skin cancer model. In addition, loss of global genomic methylation has been shown to be associated with increased aggressiveness of mouse skin cancer cell lines. However, the precise mechanism by which UV irradiation promotes melanoma remains unclear. Furthermore, there is no method for screening potential epigenetically modified genes involved in promoting skin cancers [10, 21–23]. Long-term exposure to UV irradiation is considered a major etiologic risk factor for the development of melanoma and non-melanoma skin cancers. Epigenetic alterations are generally considered to represent the interface between the environment and the genome [13]. Ultraviolet irradiation has been reported to induce epigenetic alterations, which may contribute to the development of skin cancer. In the present study, we performed global genome methylation screening using MeDIP-Seq to identify genomic loci with aberrant methylation patterns in cancer tissues.

One of the adverse effects of UV irradiation that has been observed in skin tumor development is a chronic and sustained inflammatory response. The relationship between inflammation and epigenetic modifications in cancer is under active investigation [24–26]. In this study, a UV irradiation-induced abnormal inflammatory response was suggested based on the IPA mapped IL-6 pathways, which included the methylation profiles of pro-inflammatory cytokines, receptors and mitogen-activated protein kinases. Higher levels of pro-inflammatory cytokines are associated with tumor development and progression [27, 28]. Interleukins (ILs) have different systemic functions and are involved in inflammation. Nile *et al.* reported that the methylation of CpGs in the promoter region of *IL-6* affected the mRNA levels in mononuclear cells [24]. Tekpli *et al.* reported that the methylation of CpGs near the IL-6 transcriptional start site is significantly higher in non-small cell lung cancer cells and is associated with lower IL-6 mRNA expression [25]. Our study demonstrated that IL-6 gene methylation was significantly higher in UV irradiation-induced skin tumors.

IL-6-Jak-Stat3 inflammatory signaling is also involved in cell survival and provides a proliferative advantage in the two-stage chemical carcinogenesis model using DMBA as the tumor initiator and TPA as the promoter. Phosphorylated-Stat3 overexpression in a papilloma cell line leads to enhanced cell migration and invasion [29]. Transgenic mice with constitutive Stat3 expression have a shorter latency period and increased tumor incidence compared with non-transgenic littermates after DMBA/TPA treatment [30]. Moreover, mice with constitutively activated Stat3 bypassed the premalignant stage and were initially diagnosed with carcinoma in situ, which rapidly progressed to squamous cell carcinoma. In our present study, we found 34 genes with altered DNA methylation in total 124 genes involved in the IL-6 pathway in the UV group. Among these genes with altered methylation, the SOCS1 (suppressor of cytokine signaling 1) gene, which encodes a suppressor in the IL-6-Jak-Stat3 loop, was hypermethylated in the tumor samples.

The top-ranked hypermethylated and hypomethylated genes could enable the discovery of key genes in skin cancer development. For example, RBFOX1 is the top up-regulated gene

in terms of methylation status change in UV-irradiated tumors compared with normal epidermis by IPA (Figure 1). RBFOX1 is an RNA-binding protein that is highly expressed in the cytoplasm. RBFOX1 mutations were identified in colorectal cancer cell lines (CRC), and RBFOX1 deletion was observed in a significant proportion of CRC cases (106/419) [31, 32]. However, the role of RBFOX1 in skin cancer development is unclear. Surprisingly, tumor tissues from the DMBA/TPA group exhibited a unique profile in terms of the top 50 genes with up- or down-regulated methylation compared with the profile in the UVB group. Cell adhesion molecule 2 (CADM2) was one of the top methylated genes in DMBA/TPA tumors. CADM2 belongs to a protein family that participates in maintaining cell polarity and that has been considered to be a novel category of tumor suppressors [33]. Clinically, low CADM2 expression predicts a high risk of recurrence in patients with hepatocellular carcinoma after hepatectomy [34]. It has also been reported that aberrant promoter hypermethylation and loss of CADM2 expression are associated with human renal cell carcinoma tumor progression [35]. Our study is the first report to suggest that CADM2 methylation is involved in skin carcinogenesis. Moreover, we identified changes in the methylation patterns of several genes encoding microRNAs, which are also involved in epigenetic regulation. This observation indicates that epigenetic changes may occur at multiple levels with complex crosstalk in skin cancer development and progression.

The genes identified in this study demonstrated significant alterations in response to UV irradiation-induced inflammation and skin cancer development. Although IPA revealed some overlapping signaling changes in response to both UV irradiation and DMBA-TPA treatment and certain highly affected targets were common (including, GRIA1 and TNS1), the top-ranked genes based on fold change differed markedly between the two treatments, indicating that distinct epigenetic mechanisms trigger cancer after exposure to UV or the DMBA carcinogen.

Conclusions

In this study, a comprehensive analysis of the DNA methylation patterns in the UVB or DMBA/TPA induced tumors compared with age-matched normal skin was completed. Genes coding for inflammatory cytokines were identified by IPA to exhibit altered methylation profiles and may be associated with increased susceptibility to tumor development. Specifically, based on changes in methylation, molecular networks were identified that included genes encoding inflammatory cytokines. Additional studies with a particular emphasis on epigenetic alterations, such as DNA methylation, may lead to the development of new strategies for the prevention of skin cancer and inflammation-related skin disease.

Acknowledgments

The authors would like to thank the members of Tony Kong's laboratory for their helpful discussions. This work was supported in part by institutional funds.

Abbreviations

MeDIP Methylated DNA immunoprecipitation

UVB	Ultraviolet B
DMBA	7,12-dimethylbenz(a)anthracene
TPA	12-O-tetradecanoylphorbol-1,3-acetate
IPA	Ingenuity® pathway analysis
IL	Interleukin

References

1. Esteller M. Epigenetics in cancer. *N Engl J Med*. 2008; 358(11):1148–59. [PubMed: 18337604]
2. Momparler RL, Bovenzi V. DNA methylation and cancer. *J Cell Physiol*. 2000; 183(2):145–54. [PubMed: 10737890]
3. Zingg JM, Jones PA. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. *Carcinogenesis*. 1997; 18(5):869–82. [PubMed: 9163670]
4. Baylin SB, Belinsky SA, Herman JG. Aberrant methylation of gene promoters in cancer—concepts, misconceptions, and promise. *J Natl Cancer Inst*. 2000; 92(18):1460–1. [PubMed: 10995795]
5. Laird PW, Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. *Annu Rev Genet*. 1996; 30:441–64. [PubMed: 8982461]
6. Chen WY, et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. *Nat Genet*. 2003; 33(2):197–202. [PubMed: 12539045]
7. Tommasi S, et al. Tumor susceptibility of Rassf1a knockout mice. *Cancer Res*. 2005; 65(1):92–8. [PubMed: 15665283]
8. Nandakumar V, et al. Aberrant DNA hypermethylation patterns lead to transcriptional silencing of tumor suppressor genes in UVB-exposed skin and UVB-induced skin tumors of mice. *Carcinogenesis*. 2011; 32(4):597–604. [PubMed: 21186298]
9. Koga Y, et al. Genome-wide screen of promoter methylation identifies novel markers in melanoma. *Genome Res*. 2009; 19(8):1462–70. [PubMed: 19491193]
10. Kanavy HE, Gerstenblith MR. Ultraviolet radiation and melanoma. *Semin Cutan Med Surg*. 2011; 30(4):222–8. [PubMed: 22123420]
11. Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. *Hum Mutat*. 2007; 28(6):578–88. [PubMed: 17295241]
12. Ballestar E, Esteller M. Epigenetic gene regulation in cancer. *Adv Genet*. 2008; 61:247–67. [PubMed: 18282509]
13. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet*. 2003; 33(Suppl):245–54. [PubMed: 12610534]
14. Wilkey JF, et al. Cyclin D1 overexpression increases susceptibility to 4-nitroquinoline-1-oxide-induced dysplasia and neoplasia in murine squamous oral epithelium. *Mol Carcinog*. 2009; 48(9): 853–61. [PubMed: 19263437]
15. Saab R, et al. p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor. *Cancer Res*. 2009; 69(2):440–8. [PubMed: 19147556]
16. Nishijo K, et al. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. *Cancer Res*. 2009; 69(7):2902–11. [PubMed: 19339268]
17. Zheng H, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. *Nature*. 2008; 455(7216):1129–33. [PubMed: 18948956]
18. Trapnell C, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc*. 2012; 7(3):562–78. [PubMed: 22383036]
19. Zhu LJ, et al. ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. *BMC Bioinformatics*. 2010; 11:237. [PubMed: 20459804]

20. Vaid M, Sharma SD, Katiyar SK. Honokiol, a phytochemical from the Magnolia plant, inhibits photocarcinogenesis by targeting UVB-induced inflammatory mediators and cell cycle regulators: development of topical formulation. *Carcinogenesis*. 2010; 31(11):2004–11. [PubMed: 20823108]
21. Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. *Oncogene*. 2003; 22(20):3099–112. [PubMed: 12789287]
22. Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer—the role of sunlight. *Adv Exp Med Biol*. 2008; 624:89–103. [PubMed: 18348450]
23. Moan J, Porojnicu AC, Dahlback A. Ultraviolet radiation and malignant melanoma. *Adv Exp Med Biol*. 2008; 624:104–16. [PubMed: 18348451]
24. Nile CJ, et al. Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. *Arthritis Rheum*. 2008; 58(9):2686–93. [PubMed: 18759290]
25. Tekpli X, et al. DNA methylation at promoter regions of interleukin 1B, interleukin 6, and interleukin 8 in non-small cell lung cancer. *Cancer Immunol Immunother*. 2013; 62(2):337–45. [PubMed: 22923190]
26. Gasche JA, et al. Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells. *Int J Cancer*. 2011; 129(5):1053–63. [PubMed: 21710491]
27. Mukhtar H, Elmetts CA. Photocarcinogenesis: mechanisms, models and human health implications. *Photochem Photobiol*. 1996; 63(4):356–7. [PubMed: 8934734]
28. Tron VA, Rosenthal D, Sauder DN. Epidermal interleukin-1 is increased in cutaneous T-cell lymphoma. *J Invest Dermatol*. 1988; 90(3):378–81. [PubMed: 3279133]
29. Suiqing C, Min Z, Lirong C. Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. *J Dermatol*. 2005; 32(5):354–60. [PubMed: 16043897]
30. Chan KS, et al. Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis. *Oncogene*. 2008; 27(8):1087–94. [PubMed: 17700521]
31. Cancer Genome Atlas, N. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*. 2012; 487(7407):330–7. [PubMed: 22810696]
32. Sengupta N, et al. Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion. *Mol Cancer*. 2013; 12:1. [PubMed: 23286373]
33. Chang G, et al. Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer. *Clin Cancer Res*. 2010; 16(22):5390–401. [PubMed: 21062931]
34. Yang S, et al. Low CADM2 expression predicts high recurrence risk of hepatocellular carcinoma patients after hepatectomy. *J Cancer Res Clin Oncol*. 2014; 140(1):109–16. [PubMed: 24240726]
35. He W, et al. Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression. *Biochem Biophys Res Commun*. 2013; 435(4):526–32. [PubMed: 23643812]

Figure 1. Total number of significantly up-regulated and down-regulated genes based on changes in methylation (≥ 2 -fold change) in the UVB and DMBA/TPA groups.

IL-6 Signaling

© 2000-2014 Ingenuity Systems, Inc. All rights reserved.

Figure 2.
(A) Genes mapped to the IL-6 pathway by IPA Software. Red, increased methylation; green, decreased methylation; UVB irradiated vs. control. (B) List of genes mapped to the IL-6 pathway by IPA.

Table 1

Top 50 annotated genes with up-regulated methylation ranked by log₂ fold change. (A) UVB group. (B) DMBA/TPA group.

Rank	Symbol	Gene Name	Log ₂ Fold Change (UVB/Control)	Location	Type(s)
1	RBOX1	RNA binding protein, fox-1 homolog (C. elegans) 1	5.457	Cytoplasm	other
2	IMPG2	interphotoreceptor matrix proteoglycan 2	5.367	Extracellular Space	other
3	DGKK	diacylglycerol kinase, kappa	5.31	Cytoplasm	kinase
4	MAD1L1	MAD1 mitotic arrest deficient-like 1 (yeast)	5.252	Nucleus	other
5	EVX2	even-skipped homeobox 2	5.19	Nucleus	transcription regulator
6	PAN3	PAN3 poly(A) specific ribonuclease subunit homolog (S. cerevisiae)	4.989	Cytoplasm	other
7	AAMP	angio-associated, migratory cell protein	4.837	Plasma Membrane	other
8	ARHGAP18	Rho GTPase activating protein 18	4.837	Cytoplasm	other
9	ACAA2	acetyl-CoA acyltransferase 2	4.574	Cytoplasm	enzyme
10	OLFM1	olfactomedin 1	4.574	Cytoplasm	other
11	TGS1	trimethylguanosine synthase 1	4.574	Nucleus	enzyme
12	DYM	dymeclin	4.525	Cytoplasm	other
13	Hspg2	heparan sulfate proteoglycan 2	4.474	Extracellular Space	other
14	Kcnp2	Kv channel-interacting protein 2	4.474	Plasma Membrane	other
15	TNS1	tensin 1	4.474	Plasma Membrane	other
16	AGAP1	ArfGAP with GTPase domain, ankyrin repeat and PH domain 1	4.367	Cytoplasm	enzyme
17	CCDC180	coiled-coil domain containing 180	4.367	Other	other
18	EDN1	endothelin 1	4.367	Extracellular Space	cytokine
19	FOXE1	forkhead box E1 (thyroid transcription factor 2)	4.367	Nucleus	transcription regulator
20	KCNN4	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	4.367	Plasma Membrane	ion channel
21	LOXHD1	lipoxigenase homology domains 1	4.367	Extracellular Space	other
22	DCP2	decapping mRNA 2	4.252	Nucleus	enzyme
23	DET1	de-etiolated homolog 1 (Arabidopsis)	4.252	Nucleus	other
24	DSC3	desmocollin 3	4.252	Plasma Membrane	other
25	HOXD11	homeobox D11	4.252	Nucleus	transcription regulator
26	MAML2	mastermind-like 2 (Drosophila)	4.252	Nucleus	transcription regulator

(A)					
Rank	Symbol	Gene Name	Log ₂ Fold Change (UVB/Control)	Location	Type(s)
27	MYO1E	myosin IE	4.252	Cytoplasm	enzyme
28	PCBD1	pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 alpha	4.252	Nucleus	transcription regulator
29	WNT3	wingless-type MMTV integration site family, member 3	4.252	Extracellular Space	other
30	CENPF	centromere protein F, 350/400kDa	4.126	Nucleus	other
31	Dos	downstream of SIK11	4.126	Other	other
32	FBXO11	F-box protein 11	4.126	Cytoplasm	enzyme
33	GPR37	G protein-coupled receptor 37 (endothelin receptor type B-like)	4.126	Plasma Membrane	G-protein coupled receptor
34	HPCA	hippocalcin	4.126	Cytoplasm	other
35	LIMS2	LIM and senescent cell antigen-like domains 2	4.126	Cytoplasm	other
36	LRRC8B	leucine rich repeat containing 8 family, member B	4.126	Other	other
37	LTA4H	leukotriene A4 hydrolase	4.126	Cytoplasm	enzyme
38	MEMO1	mediator of cell motility 1	4.126	Cytoplasm	other
39	mir-221	microRNA 221	4.126	Cytoplasm	microRNA
40	mir-802	microRNA 802	4.126	Cytoplasm	microRNA
41	Olfr1323	olfactory receptor 1323	4.126	Plasma Membrane	G-protein coupled receptor
42	PLN	phospholamban	4.126	Cytoplasm	transporter
43	PTPN23	protein tyrosine phosphatase, non-receptor type 23	4.126	Cytoplasm	phosphatase
44	SLC7A9	solute carrier family 7 (amino acid transporter light chain, bo,+ system), member 9	4.126	Plasma Membrane	transporter
45	VRK1	vaccinia related kinase 1	4.126	Nucleus	kinase
46	ZBTB34	zinc finger and BTB domain containing 34	4.126	Nucleus	other
47	ZNF622	zinc finger protein 622	4.126	Nucleus	other
48	SMYD2	SET and MYND domain containing 2	4.082	Cytoplasm	enzyme
49	DYSF	dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive)	3.989	Plasma Membrane	other
50	Ear2 (includes others)	eosinophil-associated, ribonuclease A family, member 2	3.989	Cytoplasm	enzyme

(B)				
Rank	Symbol	Gene Name	Log ₂ Fold Change (DMBA-TPA/Control)	Type(s)
1	FAM135A	family with sequence similarity 135, member A	5.974	enzyme

(B)					
Rank	Symbol	Gene Name	Log ₂ Fold Change (DMBA-TPA/Control)	Location	Type(s)
2	CADM2	cell adhesion molecule 2	5.231	Plasma Membrane	other
3	VWC2L	von Willebrand factor C domain containing protein 2-like	4.877	Extracellular Space	other
4	PTH2R	parathyroid hormone 2 receptor	4.708	Plasma Membrane	G-protein coupled receptor
5	NPY	neuropeptide Y	4.515	Extracellular Space	other
6	TNS1	tensin 1	4.408	Plasma Membrane	other
7	PHYHIPL	phytanoyl-CoA 2-hydroxylase interacting protein-like	4.408	Cytoplasm	other
8	COX7C	cytochrome c oxidase subunit VIIc	4.408	Cytoplasm	enzyme
9	CMYA5	cardiomyopathy associated 5	4.408	Plasma Membrane	other
10	HELB	helicase (DNA) B	4.351	Nucleus	enzyme
11	WDR63	WD repeat domain 63	4.292	Other	other
12	SIPA1L2	signal-induced proliferation-associated 1 like 2	4.292	Other	other
13	let-7	microRNA let-7a-1	4.292	Cytoplasm	microRNA
14	DSEL	dermatan sulfate epimerase-like	4.292	Extracellular Space	enzyme
15	ZNF521	zinc finger protein 521	4.167	Nucleus	other
16	TMTC2	transmembrane and tetratricopeptide repeat containing 2	4.167	Cytoplasm	other
17	OTOL1	otolin 1	4.167	Other	other
18	METTL21A	methyltransferase like 21A	4.167	Other	enzyme
19	INTU	inturned planar cell polarity protein	4.167	Cytoplasm	other
20	DHCR7	7-dehydrocholesterol reductase	4.167	Cytoplasm	enzyme
21	Cyp2a12/Cyp2a22	cytochrome P450, family 2, subfamily a, polypeptide 12	4.167	Cytoplasm	enzyme
22	CTSC	cathepsin C	4.167	Cytoplasm	peptidase
23	CHORDC1	cysteine and histidine-rich domain (CHORD) containing 1	4.167	Other	other
24	CBLN1	cerebellin 1 precursor	4.167	Cytoplasm	other
25	THAP1	THAP domain containing, apoptosis associated protein 1	4.029	Nucleus	other
26	RYBP	RING1 and YY1 binding protein	4.029	Nucleus	transcription regulator
27	NDUFA12	NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12	4.029	Cytoplasm	enzyme
28	Mug1/Mug2	murinoglobulin 1	4.029	Extracellular Space	transporter
29	MFSD10	major facilitator superfamily domain containing 10	4.029	Other	transporter
30	KIF16B	kinesin family member 16B	4.029	Cytoplasm	enzyme
31	GRID2	glutamate receptor, ionotropic, delta 2	4.029	Plasma Membrane	ion channel

(B)					
Rank	Symbol	Gene Name	Log ₂ Fold Change (DMBA-TPA/Control)	Location	Type(s)
32	Gm4836	(includes others)			
33	FOXN3	predicted gene 4836	4.029	Cytoplasm	other
34	Cyp4f16/Gm9705	forkhead box N3	4.029	Nucleus	transcription regulator
35	CXorf22	cytochrome P450, family 4, subfamily f, polypeptide 16	4.029	Cytoplasm	enzyme
36	Pag1	chromosome X open reading frame 22	4.029	Other	other
37	MSH6	phosphoprotein associated with glycosphingolipid microdomains 1	3.955	Plasma Membrane	other
38	ZFAT	mutS homolog 6	3.923	Nucleus	enzyme
39	Vmn1r188	zinc finger and AT hook domain containing	3.877	Nucleus	other
40	TYW3	vomerolateral 1 receptor 217	3.877	Plasma Membrane	G-protein coupled receptor
41	TPO	tRNA-yW synthesizing protein 3 homolog (S. cerevisiae)	3.877	Other	other
42	TLR4	thyroid peroxidase	3.877	Plasma Membrane	enzyme
43	THSD7B	toll-like receptor 4	3.877	Plasma Membrane	transmembrane receptor
44	SPINK5	thrombospondin, type I, domain containing 7B	3.877	Other	other
45	SLC9A8	serine peptidase inhibitor, Kazal type 5	3.877	Extracellular Space	other
46	SEC23A	solute carrier family 9, subfamily A (NHE8, cation proton antiporter 8), member 8	3.877	Cytoplasm	transporter
47	RPS4Y1	Sec23 homolog A (S. cerevisiae)	3.877	Cytoplasm	transporter
48	PPPIR1C	ribosomal protein S4, Y-linked 1	3.877	Cytoplasm	other
49	PARP8	protein phosphatase 1, regulatory (inhibitor) subunit 1C	3.877	Cytoplasm	phosphatase
50	NLRP4	poly (ADP-ribose) polymerase family, member 8	3.877	Other	other
		NLR family, pyrin domain containing 4	3.877	Cytoplasm	other

Table 2

Top 50 annotated genes with down-regulated methylation ranked by log₂ fold change. (A) UVB group. (B) DMBA/TPA group.

(A)				
Symbol	Gene Name	Log ₂ Fold Change (UVB/Control)	Location	Type(s)
1 Nrnx3	neurexin III	-4.543	Plasma Membrane	other
2 SYN2	synapsin II	-4.378	Plasma Membrane	other
3 Mup1 (includes others)	major urinary protein 1	-4.333	Extracellular Space	other
4 KRT86	keratin 86	-4.24	Cytoplasm	other
5 SULT1C3	sulfotransferase family, cytosolic, 1C, member 3	-4.24	Cytoplasm	enzyme
6 ATP1A3	ATPase, Na ⁺ /K ⁺ transporting, alpha 3 polypeptide	-4.191	Plasma Membrane	transporter
7 CHORDC1	cysteine and histidine-rich domain (CHORD) containing 1	-4.191	Other	other
8 NRXN1	neurexin 1	-4.191	Plasma Membrane	transporter
9 Htr6	5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled	-4.141	Plasma Membrane	G-protein coupled receptor
10 PAM	peptidylglycine alpha-amidating monooxygenase	-4.141	Plasma Membrane	enzyme
11 SERPINB3	serpin peptidase inhibitor, clade B (ovalbumin), member	-4.141	Cytoplasm	other
12 TDRD3	tudor domain containing 3	-4.141	Nucleus	transcription regulator
13 Olfr1153	olfactory receptor 1153	-4.088	Plasma Membrane	G-protein coupled receptor
14 WFIKKN2	WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2	-4.088	Other	other
15 ABAT	4-aminobutyrate aminotransferase	-4.034	Cytoplasm	enzyme
16 ARHGAP6	Rho GTPase activating protein 6	-4.034	Cytoplasm	other
17 AUH	AU RNA binding protein/enoyl-CoA hydratase	-4.034	Cytoplasm	enzyme
18 CEP70	centrosomal protein 70kDa	-4.034	Cytoplasm	other
19 DGKH	diacylglycerol kinase, eta	-4.034	Cytoplasm	kinase
20 GRIA1	glutamate receptor, ionotropic, AMPA 1	-4.034	Plasma Membrane	ion channel
21 SLC4A7	solute carrier family 4, sodium bicarbonate cotransporter, member 7	-4.034	Plasma Membrane	transporter
22 SLITRK1	SLIT and NTRK-like family, member 1	-4.034	Other	other
23 Spear4a (includes others)	spermatogenesis associated glutamate (E)-rich protein 4a	-4.034	Nucleus	other
24 CETN1	centrin, EF-hand protein, 1	-3.977	Nucleus	enzyme
25 CYLC1	cyclicin, basic protein of sperm head cytoskeleton 1	-3.977	Cytoplasm	other
26 HS3ST5	heparan sulfate (glucosamine) 3-O-sulfotransferase 5	-3.977	Cytoplasm	enzyme
27 Ott (includes others)	ovary testis transcribed	-3.977	Other	other

(A)

Symbol	Gene Name	Log ₂ Fold Change (UVB/Control)	Location	Type(s)
28 Scg5	secretogranin V	-3.977	Cytoplasm	other
29 CHM	choroideremia (Rab escort protein 1)	-3.918	Cytoplasm	enzyme
30 Clvs2	clavesin 2	-3.918	Cytoplasm	other
31 MRPS30	mitochondrial ribosomal protein S30	-3.918	Cytoplasm	enzyme
32 Olfr1010	olfactory receptor 1010	-3.918	Plasma Membrane	G-protein coupled receptor
33 PPP1R12A	protein phosphatase 1, regulatory subunit 12A	-3.918	Cytoplasm	phosphatase
34 ZMYND11	zinc finger, MYND-type containing 11	-3.918	Nucleus	other
35 ADCY10	adenylate cyclase 10 (soluble)	-3.857	Cytoplasm	enzyme
36 Agr1b	angiotensin II receptor, type 1b	-3.857	Plasma Membrane	G-protein coupled receptor
37 APAF1	apoptotic peptidase activating factor 1	-3.857	Cytoplasm	other
38 AQP1	aquaporin 1	-3.857	Plasma Membrane	transporter
39 CDH10	cadherin 10, type 2 (T2-cadherin)	-3.857	Plasma Membrane	other
40 CHRM3	cholinergic receptor, muscarinic 3	-3.857	Plasma Membrane	G-protein coupled receptor
41 GCNT2	glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group)	-3.857	Cytoplasm	enzyme
42 GNAT1	guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1	-3.857	Plasma Membrane	enzyme
43 SELENBP1	selenium binding protein 1	-3.857	Cytoplasm	other
44 SP110	SP110 nuclear body protein	-3.857	Nucleus	other
45 TMEM5	transmembrane protein 5	-3.857	Plasma Membrane	other
46 XIRP2	xin actin-binding repeat containing 2	-3.857	Other	other
47 ZKSCAN2	zinc finger with KRAB and SCAN domains 2	-3.857	Nucleus	transcription regulator
48 1700009N14R:ik	RIKEN cDNA 1700009N14 gene	-3.793	Other	transporter
49 AGPAT9	1-acylglycerol-3-phosphate O-acyltransferase 9	-3.793	Cytoplasm	enzyme
50 ASCL1	achaete-scute complex homolog 1 (Drosophila)	-3.793	Nucleus	transcription regulator

(B)

Rank	Symbol	Gene Name	Log ₂ Fold Change (DMBA-TPA/Control)	Location	Type(s)
1	EBPL	enopamil binding protein-like	-5.292	Cytoplasm	enzyme
2	PANX1	pannexin 1	-5.247	Plasma Membrane	transporter
3	HES5	hairy and enhancer of split 5 (Drosophila)	-4.632	Nucleus	other
4	LHX4	LIM homeobox 4	-4.247	Nucleus	transcription regulator

(B)					Log ₂ Fold Change (DMBA-TPA/Control)	Location	Type(s)
Rank	Symbol	Gene Name					
5	GSG1L	GSG1-like			-4.247	Plasma Membrane	other
6	PBX1	pre-B-cell leukemia homeobox 1			-4.199	Nucleus	transcription regulator
7	LRRC8B	leucine rich repeat containing 8 family, member B			-4.199	Other	other
8	ASAH2	N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2			-4.199	Cytoplasm	enzyme
9	ALKBH3	alkB, alkylation repair homolog 3 (E. coli)			-4.199	Nucleus	enzyme
10	ZNF518B	zinc finger protein 518B			-4.100	Other	other
11	MAN1A1	mannosidase, alpha, class 1A, member 1			-4.100	Cytoplasm	enzyme
12	TOX3	TOX high mobility group box family member 3			-3.993	Other	other
13	LSM11	LSM11, U7 small nuclear RNA associated			-3.936	Nucleus	other
14	TCEA3	transcription elongation factor A (SID), 3			-3.877	Nucleus	transcription regulator
15	OR7D2	olfactory receptor, family 7, subfamily D, member 2			-3.877	Plasma Membrane	G-protein coupled receptor
16	KIAA0947	KIAA0947			-3.877	Other	other
17	CBLB	Cbl proto-oncogene B, E3 ubiquitin protein ligase			-3.877	Nucleus	other
18	NOS1AP	nitric oxide synthase 1 (neuronal) adaptor protein			-3.816	Cytoplasm	other
19	MACC1	metastasis associated in colon cancer 1			-3.816	Nucleus	other
20	ZNF277	zinc finger protein 277			-3.752	Nucleus	transcription regulator
21	Sp100	nuclear antigen Sp100			-3.752	Nucleus	transcription regulator
22	KCNA6	potassium voltage-gated channel, shaker-related subfamily, member 6			-3.752	Plasma Membrane	ion channel
23	C19orf10	chromosome 19 open reading frame 10			-3.752	Extracellular Space	cytokine
24	TMEM17	transmembrane protein 17			-3.685	Extracellular Space	other
25	FAM92B	family with sequence similarity 92, member B			-3.650	Other	other
26	TBC1D5	TBC1 domain family, member 5			-3.646	Extracellular Space	other
27	Nrg1	neuregulin 1			-3.614	Extracellular Space	growth factor
28	GORASP1	golgi reassembly stacking protein 1, 65kDa			-3.614	Cytoplasm	other
29	AHRR	aryl-hydrocarbon receptor repressor			-3.614	Nucleus	other
30	ADORA2A	adenosine A2a receptor			-3.614	Plasma Membrane	G-protein coupled receptor
31	RAB11A	RAB11A, member RAS oncogene family			-3.540	Cytoplasm	enzyme
32	ISY1-RAB43	ISY1-RAB43 readthrough			-3.540	Nucleus	other
33	GNE	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase			-3.540	Cytoplasm	kinase
34	FAM98A	family with sequence similarity 98, member A			-3.540	Other	other
35	ENPP4	ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative)			-3.540	Other	enzyme

(B)

Rank	Symbol	Gene Name	Log ₂ Fold Change (DMBA-TPA/Control)	Location	Type(s)
36	CCDC43	coiled-coil domain containing 43	-3.540	Other	other
37	ARHGEF10	Rho guanine nucleotide exchange factor (GEF) 10	-3.540	Cytoplasm	enzyme
38	TARSL2	threonyl-tRNA synthetase-like 2	-3.462	Other	enzyme
39	SCARB1	scavenger receptor class B, member 1	-3.462	Plasma Membrane	transporter
40	RAB27A	RAB27A, member RAS oncogene family	-3.462	Cytoplasm	enzyme
41	L3MBTL3	l(3)mbt-like 3 (Drosophila)	-3.462	Nucleus	other
42	Higd1a	HIG1 domain family, member 1A	-3.462	Cytoplasm	other
43	GRIA1	glutamate receptor, ionotropic, AMPA 1	-3.462	Plasma Membrane	ion channel
44	GPC5	glypican 5	-3.462	Plasma Membrane	other
45	CLGN	calmegin	-3.462	Cytoplasm	peptidase
46	CHKA	choline kinase alpha	-3.462	Cytoplasm	kinase
47	ASGR1	asialoglycoprotein receptor 1	-3.462	Plasma Membrane	transmembrane receptor
48	AMY2A	amylase, alpha 2A (pancreatic)	-3.462	Extracellular Space	enzyme
49	C1orf109	chromosome 1 open reading frame 109	-3.444	Other	other
50	CADPS	Ca ⁺⁺ -dependent secretion activator	-3.430	Plasma Membrane	other

Table 3

Top 5 altered canonical pathways determined using Ingenuity Pathways Software in the UVB and DMBA/TPA groups. The shared pathways are shown in bold.

Rank	Name	Ratio	Observation/Total	p-value
<i>UVB/Control</i>				
1	cAMP-mediated signaling	0.478	108/226	1.27E-09
2	G-Protein Coupled Receptor Signaling	0.442	122/276	5.24E-09
3	Molecular Mechanisms of Cancer	0.371	144/388	9.86E-07
4	PTEN Signaling	0.42	58/138	5.21E-06
5	Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis	0.388	97/250	5.58E-06
<i>DMBA-TPA/Control</i>				
1	Protein Kinase A Signaling	0.352	144/409	5.5E-06
2	Molecular Mechanisms of Cancer	0.325	126/338	4.57E-05
3	Xenobiotic Metabolism Signaling	0.351	101/288	7.59E-05
4	Regulation of the Epithelial-Mesenchymal Transition Pathway	0.342	67/196	0.0011
5	Mouse Embryonic Stem Cell Pluripotency	0.394	39/99	0.0013

Table 4

Top 5 genes with altered methylation (up-regulated or down-regulated) that were related to skin cancer using the IPA Software Functional and Diseases analysis module in the UVB and the DMBA/TPA groups. The shared genes are shown in bold.

Rank	Mapped Genes	Log ₂ Fold Change
<i>UVB/Control</i>		
<i>Up-regulated</i>		
1	RBFOX1	5.457
2	LOXHD1	4.367
3	EDN1	4.367
4	DYSF	3.989
5	NPSR1	3.837
<i>Down-regulated</i>		
1	SULT1C3	-4.24
2	ABAT	-4.034
3	GRIA1	-4.034
4	PCSK1	-3.726
5	SCN2A	-3.655
<i>DMBA-TPA/Control</i>		
<i>Up-regulated</i>		
1	GRID2	4.029
2	NLRP4	3.877
3	EMR1	3.877
4	IL15	3.877
5	PCDH18	3.708
<i>Down-regulated</i>		
1	GRIA1	-3.462
2	CADPS	-3.43
3	BCL2L11	-3.292
4	ACVR1C	-3.292
5	GRM3	-3.292